|
KMID : 1137020100210040262
|
|
Journal of Gynecologic Oncology
2010 Volume.21 No. 4 p.262 ~ p.268
|
|
|
The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells
|
|
Jin Ke-Long
Park Jeong-Yeol
Noh Eun-Joo
Hoe Kwang-Lae
Lee Joo-Hak
Kim Jong-Hyeok
Nam Joo-Hyun
|
|
|
Abstract
|
|
|
Objective: To investigate the combined effects of cisplatin and the histone deacetylase (HDAC) inhibitors suberoylanilide hydroxamic acid (SAHA) or sirtinol on HeLa cells and assess the mechanism underlying HDAC inhibitor-cisplatin synergy.
Methods: The antineoplastic actions of cisplatin, SAHA and sirtinol, alone and in combination, were evaluated using the tetrazolium dye-based MTT cell proliferation assay, DAPI nuclear staining and cytotoxicity analysis.
Results: Exposure to cisplatin, SAHA or sirtinol alone induced a dose-dependent reduction in HeLa cell viability. Combined treatment with cisplatin and SAHA or sirtinol was significantly more cytotoxic than cisplatin alone. Individually, cisplatin, SAHA and sirtinol activated caspase-3 and induced apoptosis, but the effects of combined treatment were greater. Importantly, both HDAC inhibitors dose-dependently inhibited the expression of the antiapoptotic proteins Bcl-2 and x-linked inhibitor of apoptosis protein (XIAP).
Conclusion: The combination of cisplatin and SAHA or sirtinol had synergistic effect on the HeLa cell viability. This potentiation of cisplatin activity was associated with HDAC inhibitor-mediated down-regulation of Bcl-2 and XIAP. These may result from the relaxation of chromatin by these HDAC inhibitors that increase cisplatin sensitivity by enhancing the accessibility of DNA to cisplatin and transcriptional regulators.
|
|
|
KEYWORD
|
|
|
Cervical cancer, Apoptosis, Cisplatin, Suberoylanilide hydroxamic acid, Sirtinol
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
    
|